BPC-157

Last updated

Contents

BPC-157
BPC-157.svg
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
DrugBank
PubChem CID
UNII
  • InChI=1S/C62H98N16O22/c1-31(2)25-37(55(92)74-50(32(3)4)62(99)100)71-46(81)29-65-51(88)33(5)67-53(90)38(26-48(84)85)73-54(91)39(27-49(86)87)72-52(89)34(6)68-57(94)41-15-10-21-75(41)58(95)35(13-7-8-20-63)70-45(80)30-66-56(93)40-14-9-22-76(40)60(97)43-17-12-24-78(43)61(98)42-16-11-23-77(42)59(96)36(18-19-47(82)83)69-44(79)28-64/h31-43,50H,7-30,63-64H2,1-6H3,(H,65,88)(H,66,93)(H,67,90)(H,68,94)(H,69,79)(H,70,80)(H,71,81)(H,72,89)(H,73,91)(H,74,92)(H,82,83)(H,84,85)(H,86,87)(H,99,100)/t33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,50-/m0/s1
    Key: HEEWEZGQMLZMFE-RKGINYAYSA-N
  • C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN
Properties
C62H98N16O22
Molar mass 1419.556 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN (what is  Yes check.svgYX mark.svgN ?)

Gastric Pentadecapeptide BPC-157 (also known as PL 14736, Body Protection Compound 157, or bepecin) is a fifteen amino acid long oligopeptide that was discovered during research on human gastric juice. [1] The amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. [2]

BPC-157 is stable at room temperature and bioavailable in rodent models when administered IM or IV. [3]

Research

Pre-clinical research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing. [4] [5] [6] [7] [8] [9]

This substance is sometimes used in functional medicine despite not being approved by any drug regulatory agency. [10] The compound promotes angiogenesis and as a result has some concerns over cancer promotion. [11]

As of 2022, the peptide was temporarily banned by the World Anti-Doping Agency under the S0 category of non-exempt substances. [12]

BPC-157 has been widely used both by athletes and among the general public, mainly for recovery from injury or stimulating healing in chronic conditions, [13] [14] [15] [16] but there is as yet only very limited human trial data on efficacy and only a few preliminary safety studies, [17] [18] [19] so use of BPC-157 is discouraged by health authorities and it has been controlled as a prescription medicine in several jurisdictions such as New Zealand and Australia, despite not actually being available for prescription. [20] [21]

Detection

BPC-157 is detected in urine using a weak cation exchange solid phase extraction and was found to be stable in urine for 4 days. [22]

References

  1. ↑ Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration". Journal of Applied Physiology. 110 (3). American Physiological Society: 774–780. doi:10.1152/japplphysiol.00945.2010. ISSN   8750-7587. PMID   21030672.
  2. ↑ Jelovac N, Sikiric P, Rucman R, Petek M, Marovic A, Perovic D, et al. (August 1999). "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats". European Journal of Pharmacology. 379 (1): 19–31. doi:10.1016/S0014-2999(99)00486-0. PMID   10499368.
  3. ↑ He L, Feng D, Guo H, Zhou Y, Li Z, Zhang K, et al. (2022-12-14). "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs". Frontiers in Pharmacology. 13 1026182. Frontiers Media SA. doi: 10.3389/fphar.2022.1026182 . ISSN   1663-9812. PMC   9794587 . PMID   36588717.
  4. ↑ Vukojevic J, Milavić M, Perović D, Ilić S, Čilić AZ, Đuran N, et al. (March 2022). "Pentadecapeptide BPC 157 and the central nervous system". Neural Regeneration Research. 17 (3): 482–487. doi: 10.4103/1673-5374.320969 . PMC   8504390 . PMID   34380875.
  5. ↑ Chang C, Tsai W, Lin M, Hsu Y, Pang JS (October 28, 2010). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration" . Journal of Applied Physiology. 110 (3): 774–780. doi:10.1152/japplphysiol.00945.2010. PMID   21030672.
  6. ↑ Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, et al. (2003). "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth" . Journal of Orthopaedic Research. 21 (6): 976–983. doi:10.1016/S0736-0266(03)00110-4. PMID   14554208.
  7. ↑ Sikiric P, Seiwerth S, Rucman R, Turkovic B, Rokotov DS, Brcic L, et al. (2011). "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract". Current Pharmaceutical Design. 17 (16): 1612–32. doi:10.2174/138161211796196954. PMID   21548867.
  8. ↑ Sikiric P, Seiwerth S, Brcic L, Blagaic AB, Zoricic I, Sever M, et al. (December 2006). "Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response". Inflammopharmacology. 14 (5–6): 214–221. doi:10.1007/s10787-006-1531-7. PMID   17186181. S2CID   24132425.
  9. ↑ Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, et al. (September 2010). "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat". Journal of Orthopaedic Research. 28 (9): 1155–1161. doi:10.1002/jor.21107. PMID   20225319. S2CID   22085833.
  10. ↑ Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, et al. (2016). "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications". Current Neuropharmacology. 14 (8): 857–865. doi:10.2174/1570159x13666160502153022. PMC   5333585 . PMID   27138887.
  11. ↑ Sehgal P, Gupta R, Choudhary K, Singh R (2025). "BPC 157: A Promising Candidate for Cytoprotection and Tissue Repair". Pharmaceuticals. 18 (2). MDPI: 185. doi: 10.3390/ph18020185 . ISSN   1424-8247. PMC   11859134 . PMID   40005999.
  12. ↑ "2022 Prohibited List: SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)" (PDF). World Anti-Doping Agency. WADA. Retrieved 21 February 2022.
  13. ↑ Defoor MT, Dekker TJ (2025). "Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance?". Arthroscopy. 41 (2): 150–152. doi:10.1016/j.arthro.2024.09.005. PMID   39265666.
  14. ↑ Józwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). "Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review". Pharmaceuticals. 18 (2): 185. doi: 10.3390/ph18020185 . PMC   11859134 . PMID   40005999.
  15. ↑ Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, et al. (2025). "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review". HSS Journal 15563316251355551. doi:10.1177/15563316251355551. PMC   12313605 . PMID   40756949.
  16. ↑ McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM (2025). "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing". Current Reviews in Musculoskeletal Medicine. 18 (12): 611–619. doi:10.1007/s12178-025-09990-7. PMC   12446177 . PMID   40789979.
  17. ↑ Xu C, Sun L, Ren F, Huang P, Tian Z, Cui J, et al. (2020). "Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds". Regulatory Toxicology and Pharmacology. 114 104665. doi:10.1016/j.yrtph.2020.104665. PMID   32334036.
  18. ↑ Lee E, Padgett B (2021). "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain". Alternative Therapies in Health and Medicine. 27 (4): 8–13. PMID   34324435.
  19. ↑ Lee E, Walker C, Ayadi B (2024). "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study". Alternative Therapies in Health and Medicine. 30 (10): 12–17. PMID   39325560.
  20. ↑ Notice of interim decisions to amend (or not amend) the current Poisons Standard. Therapeutic Goods Administration, 3 April 2024
  21. ↑ Classification of Unscheduled Peptides. Submission to the Medicines Classification Committee. Medsafe, June 2025
  22. ↑ Cox HD, Miller GD, Eichner D (2017). "Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H". Drug Testing and Analysis. 9 (10): 1490–1498. doi:10.1002/dta.2152. ISSN   1942-7603. PMID   28035768.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.